TAFA4/FAM19A4 Antibody (480103) [Alexa Fluor™ Plus 555]

• Reactivity: Hu
• Clone: 480103
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 555

TAFA4/FAM19A4 Antibody (480103) [Alexa Fluor™ Plus 555] Summary

• Specificity: Detects human TAFA4/FAM19A4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross‑reactivity with recombinant human TAFA1, 2, 3, or 5 is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TAFA4/FAM19A4 Antibody (480103) [Alexa Fluor™ Plus 555]

• Chemokine-like protein TAFA-4
• FAM19A4
• family with sequence similarity 19 (chemokine (C-C motif)-like), member A4
• FLJ25161
• TAFA4
• TAFA-4

Background

TAFA4 (also FAM19A4) is a secreted, 12 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 140 amino acid (aa) precursor that contains a 35 aa signal sequence and a 105 aa mature chain. Like other members of the FAM19/TAFA family, with the exception of TAFA5, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern Cx₇CCx₁₃CxCx₁₄Cx₁₁Cx₄Cx₅Cx₁₀C, where C represents a conserved cysteine residue and x represents any noncysteine amino acid (1). Human TAFA4 is 90% aa identical to mouse TAFA4 (1). Real-time PCR analysis indicates that TAFA4 mRNA expression is restricted to the central nervous system (CNS), with the highest level in the thalamus (1). TAFAs may modulate immune responses in the CNS by functioning as brain specific chemokines and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1, 2). TAFAs may also control axonal sprouting following brain injury (1).

1. Tang, Y.T. et al. (2004) Genomics 83:727.
2. Benveniste, E. (1998) Cytokine Growth Factor Rev. 9:259.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.